TRP_1170x120_3-8-19

Erelzi (etanercept-szzs)

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi U.S. patent case

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi U.S. patent case

HOLZKIRCHEN, Germany  – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States District Court of New Jersey ruled against Sandoz in patent litigation concerning the Sandoz biosimilar, Erelzi (etanercept-szzs) for reference medicine Enbrel (etanercept). The company will appeal the ruling to the US Court of Appeals for the